References

  1. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. Phase II study of weekly intravenous trastuzumab (herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Seminars in Oncology. 1999;26(4 Suppl 12):78–83. [PubMed: 10482197]
  2. Benowitz NL, Pomerleau OF, Pomerleau CS, Jacob P 3rd. Nicotine metabolite ratio as a predictor of cigarette consumption. Nicotine and Tobacco Research. 2003;5(5):621–624. [PubMed: 14577978]
  3. Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ. Effect of screening and adjuvant therapy on mortality from breast cancer. New England Journal of Medicine. 2005;353(17):1784–1792. [PubMed: 16251534]
  4. Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. Journal of the American Medical Association. 2006;295(14):1658–1667. [PMC free article: PMC1459540] [PubMed: 16609087]
  5. Brass EP. The gap between clinical trials and clinical practice: The use of pragmatic clinical trials to inform regulatory decision making. Clinical Pharmacology & Therapeutics. 2010;87(3):351–355. [PubMed: 20010554]
  6. de Jong AE, Hendriks YM, Kleibeuker JH, de Boer SY, Cats A, Griffioen G, Nagengast FM, Nelis FG, Rookus MA, Vasen HF. Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology. 2006;130(3):665–671. [PubMed: 16530507]
  7. Evans WK, Laupacis A, Gulenchyn KY, Levin L, Levine M. Evidence-based approach to the introduction of positron emission tomography in Ontario, Canada. Journal of Clinical Oncology. 2009;27(33):5607–5613. [PubMed: 19858395]
  8. Goeree R, Levin L. Building bridges between academic research and policy formulation: The PRUFE framework—an integral part of Ontario's evidence-based HTPA process. Pharmacoeconomics. 2006;24(11):1143–1156. [PubMed: 17067198]
  9. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, Watsky EJ, Gong J, Williams KE, Reeves KR. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: A randomized controlled trial. Journal of the American Medical Association. 2006;296(1):47–55. [PubMed: 16820546]
  10. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC Jr. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. Journal of Clinical Oncology. 2007;25(33):5287–5312. [PubMed: 17954709]
  11. Imperiale TF, Wagner DR, Lin CY, Larkin GN, Rogge JD, Ransohoff DF. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. New England Journal of Medicine. 2000;343(3):169–174. [PubMed: 10900275]
  12. Imperiale TF, Glowinski EA, Lin-Cooper C, Larkin GN, Rogge JD, Ransohoff DF. Five-year risk of colorectal neoplasia after negative screening colonoscopy. New England Journal of Medicine. 2008;359(12):1218–1224. [PubMed: 18799558]
  13. IOM (Institute of Medicine) The value of genetic and genomic technologies: Workshop summary. Washington, DC: The National Academies Press; 2010.
  14. IOM. Establishing precompetitive collaborations to stimulate genomics-driven product development: Workshop summary. Washington, DC: The National Academies Press; 2011. [PubMed: 21595119]
  15. Jarvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomaki P, Chapelle ADL, Mecklin JP. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118(5):829–834. [PubMed: 10784581]
  16. Lee JJ, Chu E. First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer. Clinical Colorectal Cancer. 2007;6(Suppl 2):S42–S46. [PubMed: 18021486]
  17. Levin L, Goeree R, Sikich N, Jorgensen B, Brouwers MC, Easty T, Zahn C. Establishing a comprehensive continuum from an evidentiary base to policy development for health technologies: The Ontario experience. International Journal of Technology Assessment in Health Care. 2007;23(3):299–309. [PubMed: 17579931]
  18. Malaiyandi V, Goodz SD, Sellers EM, Tyndale RF. CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking. Cancer Epidemiology, Biomarkers & Prevention. 2006;15(10):1812–1819. [PubMed: 17035386]
  19. Marchionni L, Wilson RF, Marinopoulos SS, Wolff AC, Parmigiani G, Bass EB, Goodman SN. Impact of gene expression profiling tests on breast cancer outcomes Evidence report/technology assessment no. 160. Agency for Healthcare Research and Quality Publication No. 08-E002. 2008 January prepared by the Johns Hopkins University Evidence-Based Practice Center under contract no. 290-02-0018. [PubMed: 18457476]
  20. MAS (Medical Advisory Secretariat) Endovascular repair of abdominal aortic aneurysms in low surgical risk patients: Rapid review. Toronto, ON: Medical Advisory Secretariat; 2010. [March 24, 2011]. Available at http://www​.health.gov​.on.ca/english/providers​/program/mas/tech​/rapid/pdf/rr_evar_20100113.pdf.
  21. Moss AJ, Shimizu W, Wilde AA, Towbin JA, Zareba W, Robinson JL, Qi M, Vincent GM, Ackerman MJ, Kaufman ES, Hofman N, Seth R, Kamakura S, Miyamoto Y, Goldenberg I, Andrews ML, McNitt S. Clinical aspects of type-1 long-QT syndrome by location, coding type, and biophysical function of mutations involving the KCNQ1 gene. Circulation. 2007;115(19):2481–2489. [PMC free article: PMC3332528] [PubMed: 17470695]
  22. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. New England Journal of Medicine. 2004;351(27):2817–2826. [PubMed: 15591335]
  23. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner R, Walker M, Watson D, Bryant J, Wolmark N. Risk classification of breast cancer patients by the recurrence score assay: Comparison to guidelines based on patient age, tumor size, and tumor grade. Paper read at 27th Annual San Antonio Breast Cancer Symposium; December 8-11, 2004; San Antonio, TX. 2004.
  24. Paik S, Tang G, Shak S, Kim C, Baker J, Kim W, Cronin M, Baehner FL, Watson D, Bryant J, Costantino JP, Geyer CE Jr, Wickerham DL, Wolmark N. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. Journal of Clinical Oncology. 2006;24(23):3726–3734. [PubMed: 16720680]
  25. Palomaki GE, McClain MR, Melillo S, Hampel HL, Thibodeau SN. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. Genetics in Medicine. 2009;11(1):42–65. [PMC free article: PMC2743613] [PubMed: 19125127]
  26. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond. Statistics in Medicine. 2008;27(2):157–172. discussion 207-212. [PubMed: 17569110]
  27. Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P. Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. American Journal of Epidemiology. 2004;59(9):882–890. [PubMed: 15105181]
  28. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer deaths down 25% in year 2000 at ages 20-69 years. Lancet. 2000;355(9217):1822. [PubMed: 10832853]
  29. Ray R, Tyndale RF, Lerman C. Nicotine dependence pharmacogenetics: Role of genetic variation in nicotine-metabolizing enzymes. Journal of Neurogenetics. 2009;23(3):252–261. [PMC free article: PMC3772540] [PubMed: 19169923]
  30. Roden DM. Clinical practice. Long-QT syndrome. New England Journal of Medicine. 2008;358(2):169–176. [PubMed: 18184962]
  31. Schmeler KM, Lynch HT, Chen LM, Munsell MF, Soliman PT, Clark MB, Daniels MS, White KG, Boyd-Rogers SG, Conrad PG, Yang KY, Rubin MM, Sun CC, Slomovitz BM, Gershenson DM, Lu KH. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. New England Journal of Medicine. 2006;354(3):261–269. [PubMed: 16421367]
  32. Shao YY. Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer, Discovery Medicine. Jun, 2010. [March 25]. 2010. Available at http://www​.discoverymedicine​.com/Yu-Yun-Shao​/2010/06/19/gefitinib-or-erlotinib-in-the-treatment-of-advanced-non-small-cell-lung-cancer/ [PubMed: 20587343]
  33. Simon RM, Paik S, Hayes DF. Use of archived specimens in evaluation of prognostic and predictive biomarkers. Journal of the National Cancer Institute. 2009;101(21):1446–1452. [PMC free article: PMC2782246] [PubMed: 19815849]
  34. Tarride JE, Blackhouse G, De Rose G, Novick T, Bowen JM, Hopkins R, O'Reilly D, Goeree R. Cost-effectiveness analysis of elective endovascular repair compared with open surgical repair of abdominal aortic aneurysms for patients at a high surgical risk: A 1-year patient-level analysis conducted in Ontario, Canada. Journal of Vascular Surgery. 2008;48(4):779–787. [PubMed: 18639421]
  35. TEC (Blue Cross and Blue Shield Association Technology Evaluation Center) Gene expression profiling for managing breast cancer treatment. Technology Evaluation Center Assessment Program. 2005;20(3):1–5. [PubMed: 15940843]
  36. TEC. Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer. Technology Evaluation Center Assessment Program. 2007;22(6):1–22. [PubMed: 18080406]
  37. TEC. Gene expression profiling of breast cancer to select women for adjuvant chemotherapy. Technology Evaluation Center Assessment Program. 2008;22(13):1–8. [PubMed: 18663816]
  38. TEC. Genetic testing for long-QT syndrome. Technology Evaluation Center Assessment Program. 2008;22(9):1–5. [PubMed: 18411500]
  39. TEC. Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer. Technology Evaluation Center Assessment Program. 2011;25(6):1–30. [PubMed: 21638942]
  40. Teutsch SM, Bradley LA, Palomaki GE, Haddow JE, Piper M, Calonge N, Dotson WD, Douglas MP, Berg AO. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: Methods of the EGAPP working group. Genetics in Medicine. 2009;11(1):3–14. [PMC free article: PMC2743609] [PubMed: 18813139]
  41. Tu JV, Bowen J, Chiu M, Ko DT, Austin PC, He Y, Hopkins R, Tarride JE, Blackhouse G, Lazzam C, Cohen EA, Goeree R. Effectiveness and safety of drug-eluting stents in Ontario. New England Journal of Medicine. 2007;357(14):1393–1402. [PubMed: 17914040]
  42. Villanueva J, Shaffer DR, Philip J, Chaparro CA, Erdjument-Bromage H, Olshen AB, Fleisher M, Lilja H, Brogi E, Boyd J, Sanchez-Carbayo M, Holland EC, Cordon-Cardo C, Scher HI, Tempst P. Differential exoprotease activities confer tumor-specific serum peptidome patterns. Journal of Clinical Investigation. 2006;116(1):271–284. [PMC free article: PMC1323259] [PubMed: 16395409]
  43. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Journal of Clinical Oncology. 2007;25(1):118–145. [PubMed: 17159189]
  44. Zhu CQ, da Cunha Santos G, Ding K, Sakurada A, Cutz JC, Liu N, Zhang T, Marrano P, Whitehead M, Squire JA, Kamel-Reid S, Seymour L, Shepherd FA, Tsao MS. Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. Journal of Clinical Oncology. 2008;26(26):4268–4275. [PubMed: 18626007]
  45. Zujewski JA, Kamin L. Trial assessing individualized options for treatment for breast cancer: The TAILORx trial. Future Oncology. 2008;4(5):603–610. [PubMed: 18922117]